Results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen
| Response category . | No. (%) . | Marrow FL-C negative, n/N (%) . | Marrow PCR negative, n/N (%) . | Time to progression . | Overall survival . | ||
|---|---|---|---|---|---|---|---|
| Median, mo . | 6-y prog free, % . | Median, mo . | 6-y surv, % . | ||||
| Complete response | 217 (72) | 173/210 (82) | 73/173 (42) | 85 | 67 | Not reached | 88 |
| Nodular partial response | 31 (10) | 10/26 (39) | 8/22 (36) | 71 | 49 | Not reached | 77 |
| Partial response due to cytopenia (PR-i) | 21 (7) | 11/20 (55) | 4/13 (31) | 50 | 31 | 66 | 42 |
| Partial response due to residual disease (PR-d) | 16 (5) | 1/10 (10) | 0/4 (0) | 19 | - | 34 | 24* |
| Failure | |||||||
| Resistant disease | 13 (4) | 0/10 (0) | - | - | - | 20 | 15* |
| Death within 3 mo | 2 (<1) | - | - | - | - | 1 | - |
| Response category . | No. (%) . | Marrow FL-C negative, n/N (%) . | Marrow PCR negative, n/N (%) . | Time to progression . | Overall survival . | ||
|---|---|---|---|---|---|---|---|
| Median, mo . | 6-y prog free, % . | Median, mo . | 6-y surv, % . | ||||
| Complete response | 217 (72) | 173/210 (82) | 73/173 (42) | 85 | 67 | Not reached | 88 |
| Nodular partial response | 31 (10) | 10/26 (39) | 8/22 (36) | 71 | 49 | Not reached | 77 |
| Partial response due to cytopenia (PR-i) | 21 (7) | 11/20 (55) | 4/13 (31) | 50 | 31 | 66 | 42 |
| Partial response due to residual disease (PR-d) | 16 (5) | 1/10 (10) | 0/4 (0) | 19 | - | 34 | 24* |
| Failure | |||||||
| Resistant disease | 13 (4) | 0/10 (0) | - | - | - | 20 | 15* |
| Death within 3 mo | 2 (<1) | - | - | - | - | 1 | - |
Response categories were that of the National Cancer Institute (NCI) 1996 guidelines with the exception of partial response due to residual disease, which included patients meeting all clinical and laboratory parameters for complete response but with incomplete marrow recovery (hemoglobin level < 110 g/L, neutrophil count < 1.5 × 109/L, and/or platelet count < 100 × 109/L). Total numbers (N) in columns 3 and 4 are smaller than column 2 because not all patients had FL-C on PCR testing.
Results at 5 years.